It was also indicated that the effects of TWEAK are possibly due to its regulation of PGC-1α and MuRF1, and thus these factors may be potential targets in the treatment of muscle atrophy in COPD. Here, PPARGC1A is linked to chronic obstructive pulmonary disease.